IRIS
RUMI, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.996
EU - Europa 2.133
AS - Asia 1.381
Continente sconosciuto - Info sul continente non disponibili 11
AF - Africa 7
OC - Oceania 5
SA - Sud America 2
Totale 6.535
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.964
CN - Cina 1.363
IE - Irlanda 866
FI - Finlandia 321
UA - Ucraina 275
DE - Germania 191
IT - Italia 173
SE - Svezia 129
GB - Regno Unito 73
FR - Francia 37
CA - Canada 32
RO - Romania 24
BE - Belgio 12
NL - Olanda 10
IN - India 9
RU - Federazione Russa 8
EU - Europa 7
MU - Mauritius 6
AU - Australia 5
CH - Svizzera 5
A2 - ???statistics.table.value.countryCode.A2??? 2
BG - Bulgaria 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
PL - Polonia 2
XK - ???statistics.table.value.countryCode.XK??? 2
AR - Argentina 1
AT - Austria 1
CL - Cile 1
EG - Egitto 1
ES - Italia 1
GR - Grecia 1
HK - Hong Kong 1
MY - Malesia 1
QA - Qatar 1
SA - Arabia Saudita 1
SG - Singapore 1
TR - Turchia 1
TW - Taiwan 1
Totale 6.535
Salva come PNG Salva come JPEG
Città #
Dublin 865
Chandler 643
Jacksonville 423
Nanjing 392
Ashburn 276
Princeton 168
Nanchang 163
Lawrence 159
Beijing 139
Wilmington 121
Shenyang 116
Hebei 110
Changsha 106
Helsinki 103
Medford 101
New York 93
Jiaxing 91
Ann Arbor 79
Tianjin 61
Hangzhou 58
Shanghai 49
Boardman 47
Milan 34
Woodbridge 29
Norwalk 28
Toronto 28
Pavia 25
Seattle 22
Timisoara 22
Washington 20
Los Angeles 17
Fairfield 15
Jinan 13
Brussels 12
Verona 12
Auburn Hills 10
Falls Church 9
Florence 9
Zhengzhou 9
Ningbo 7
Pune 7
Des Moines 6
Guangzhou 6
Taizhou 6
Monmouth Junction 5
Orange 5
Rome 5
Dearborn 4
Fuzhou 4
Gallarate 4
San Francisco 4
Brugherio 3
Canberra 3
Fano 3
Fiesole 3
Houston 3
Kunming 3
Lugano 3
Redwood City 3
Saint Paul 3
San Luis Obispo 3
Tappahannock 3
Andover 2
Antony 2
Borås 2
Chicago 2
Dronten 2
Falkenstein 2
Frankfurt am Main 2
Genoa 2
Gießen 2
Haikou 2
Kemerovo 2
Lanzhou 2
Leawood 2
Manchester 2
Monza 2
Paderno Dugnano 2
Paris 2
Sofia 2
Srbica 2
The Bronx 2
Almere Stad 1
Amsterdam 1
Basel 1
Berlin 1
Bolgare 1
Boston 1
Bovisio Masciago 1
Buffalo 1
Cadoneghe 1
Cairo 1
Changchun 1
Chesterfield 1
Collegeville 1
Como 1
Cothen 1
Doha 1
Dundalk 1
Edmonton 1
Totale 4.831
Salva come PNG Salva come JPEG
Nome #
A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis 88
A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. 75
Bone marrow microvessel density in chronic myeloproliferative disorders: a study of 115 patients with clinicopathological and molecular correlations 75
Blood p50 evaluation enhances diagnostic definition of isolated erythrocytosis. 75
CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis 73
High resolution genome-wide array-comparative genomic hybridization in splenic marginal zone B-cell lymphoma 72
Tie2 expressing monocytes in the spleen of patients with primary myelofibrosis 70
Blast phase of essential thrombocythemia: A single center study. 69
Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis 69
Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients 69
An insidious presentation of splenic marginal zone lymphoma 68
Clinical significance of neutrophil CD177 mRNA expression in Ph-negative chronic myeloproliferative disorders 66
Complex Patterns of Chromosome 11 Aberrations in Myeloid Malignancies Target CBL, MLL, DDB1 and LMO2. 65
JAK2 (V617F) mutation in healthy individuals 64
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia. 64
Peripheral intraneutrophil diplococci in a case of meningococcemia. 64
Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms 64
The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. 63
Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. 63
Cardiovascular events and intensity of treatment in polycythemia vera. 59
Clinical significance of somatic mutation in unexplained blood cytopenia 59
PRV-1 and its correlation with treatments and disease status in 210 patients with polycythemia vera and essential thrombocythemia 58
Correlation of the FLIPI score for follicular lymphoma with period of diagnosis and type of treatment 57
Incidence of leukaemia in patients with primary myelofibrosis and RBC-transfusion-dependence. 57
Familial chronic myeloproliferative disorders: the state of the art 56
Impact of treatment-related liver toxicity on the outcome of HCV-positive non-Hodgkin's lymphomas. 56
Clinical relevance of murine double minute 2 single nucleotide polymorphisms 309 in familial myeloproliferative neoplasm. 56
Bone marrow histology in marginal zone B-cell lymphomas: correlation with clinical parameters and flow cytometry in 120 patients 56
Long-term follow-up of young patients with essential thrombocythemia treated with pipobroman. 55
Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. 55
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms 55
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 55
Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics. 55
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients 55
JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders 55
Flow-FISH evaluation of telomere length in Philadelphia-negative myeloproliferative neoplasms. 54
Mutational analysis of BCORL1 in the leukemic transformation of chronic myeloproliferative neoplasms. 54
Allelic imbalance in CALR somatic mutagenesis 54
Increase in leukocyte count over time predicts thrombosis in patients with low-risk essential thrombocythemia. 54
Role of the molecular staging and response in the management of follicular lymphoma patients 53
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: An international study of 264 patients. 52
Clinical significance of genetic aberrations in secondary acute myeloid leukemia. 52
Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders 52
Identification of genomic aberrations associated with disease transformation by means of high-resolution SNP array analysis in patients with myeloproliferative neoplasm 51
Mutation Type As a Major Determinant of Clinical Phenotype in Myeloproliferative Neoplasms Associated with Mutant Calreticulin 51
Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. 50
Clinical relevance of JAK2 (V617F) mutant allele burden 50
Increased risk of lymphoid neoplasm in patients with myeloproliferative neoplasm: a study of 1,915 patients. 49
A novel germline JAK2 mutation in familial myeloproliferative neoplasms. 49
Advances in understanding the pathogenesis of familial myeloproliferative neoplasms 49
Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms 49
Clinical utility of the absolute number of circulating CD34-positive cells in patients with chronic myeloproliferative disorders. 49
Molecular remission after allo-SCT in a patient with post-essential thrombocythemia myelofibrosis carrying the MPL (W515A) mutation. 48
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia 48
Co-mutation pattern, clonal hierarchy, and clone size concur to determine disease phenotype of SRSF2 P95-mutated neoplasms 48
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. 47
Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. 47
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 47
Splenic marginal zone B-cell lymphoma in a HIV-positive patient: a case report 46
Splenic marginal zone lymphoma: clinical clustering of immunoglobulin heavy chain repertoires 46
Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. 46
LIVER BIOPSY DURING SPLENECTOMY REVEALS THAT SPLENIC MARGINAL ZONE LYMPHOMA IS OFTEN AN HEPATO-SPLENIC DISEASE 45
A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 Inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea 45
Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation 45
Improving survival trends in primary myelofibrosis: an international study. 45
Mutational status of myeloproliferative neoplasms. 44
Efficacy of ruxolitinib in chronic eosinophilic leukemia associated with a PCM1-JAK2 fusion gene. 44
Mutations and prognosis in primary myelofibrosis 44
Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases 44
Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression 44
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera. 43
Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation 43
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment 43
Myelofibrotic transformation in essentialthrombocythemia. Author reply 42
Dyspnea secondary to pulmonary hematopoiesis as presenting symptom of myelofibrosis with myeloid metaplasia 42
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment) 42
Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. 42
LNK mutations in familial myeloproliferative neoplasms. 42
JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms. 41
Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia 41
Common germline variation at the TERT locus contributes to familial clustering of myeloproliferative neoplasms 41
Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. 41
Pregnancy complications predict thrombotic events in young women with essential thrombocythemia 40
Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS. 40
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. 40
Diagnosis and management of prefibrotic myelofibrosis. 40
Deletions of the transcription factor Ikaros in myeloproliferative neoplasms 39
Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene 39
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology. 39
Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. 39
HLA typing and VH gene rearrangement analysis in a family with hairy cell leukaemia 38
How I treat essential thrombocythemia. 38
Somatic mutations of calreticulin in myeloproliferative neoplasms 38
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. 37
Masked polycythemia vera diagnosed according to WHO and BCSH classification 37
Long term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. 34
Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders 34
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. 34
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms. 34
Platelet count predicts driver mutations’ co-occurrence in low JAK2 mutated essential thrombocythemia and myelofibrosis 34
Totale 5.087
Salva come PNG Salva come JPEG
Categoria #
all - tutte 26.979
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 26.979
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201924 0 0 0 0 0 0 0 0 0 0 3 21
2019/20201.573 479 646 4 50 3 60 18 95 27 146 41 4
2020/2021605 74 48 13 62 4 62 10 106 53 89 66 18
2021/2022693 9 4 23 11 17 38 6 38 33 38 115 361
2022/20232.091 223 118 21 135 204 169 1 100 992 13 87 28
2023/2024938 119 170 55 70 96 302 27 66 10 22 1 0
Totale 6.876